Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

• DOI: 10.2340/actadv.v101.283
• Publication Date: 2021-10-01T10:39:50Z
• Authors: Riccardo G. Borroni; Piergiorgio Malagoli; Luigi Gargiulo; Mario Valenti; Giulia Pavia; Paola Facheris; Emanuela Morenghi; Isotta Giunipero ...; Alessandra Narcisi; Michela Ortoncelli; Paolo Dapavo; Antonio Costanzo
• Keywords: Adult; Clinical Report; Antibodies, Monoclonal; psoriasis; Dermatology; risankizumab; Severity of Illness Index; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; RL1-803; Humans; Psoriasis; real-life; Retrospective Studies

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It approved for treatment moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated risankizumab in monotherapy up to week 40 "real-life" setting. At 40, 98.7%, 85.7% and 62.3% patients achieved Psoriasis Area Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 100, respectively. Patients who had not responded 2 or more previous biologic treatments were significantly less likely achieve 75/90 at 16 90/100 compared those been previously only 1 biologic, as first-line biologic. Increasing body mass index decreased chances reaching 40. No significant safety findings recorded throughout study, none interrupt treatment. These data suggest efficacy clinical practice could differ from pivotal trials data.